Daudi

DAUDI (Burkitt’s Lymphoma CDX Model) 

The DAUDI cell line was derived from a patient with Burkitt’s lymphoma. It represents an Epstein–Barr virus (EBV)-positive B-cell lymphoma model. DAUDI has been a cornerstone for hematology research and drug development. Its growth characteristics make it useful in studying B-cell malignancies and targeted therapies. 

Key Features: 

• Derived from Burkitt’s lymphoma. 

• EBV-positive B-cell line. 

• Strong growth in suspension culture. 

• Useful for lymphoma drug discovery. 

Applications: 
DAUDI supports studies of B-cell lymphoma biology and immunotherapy evaluation. It is frequently used to test cytotoxic agents and targeted therapies. Researchers employ it to study EBV-associated oncogenesis. Its reproducibility has made it a standard in hematologic oncology research.